Summary
Experimental allergic encephalomyelitis (EAE) is induced in susceptible animals by immunodominant determinants of myelin basic protein (MBP). Analogs of these disease-associated peptides have been identified with disease progression upon coimmunization. Usage of peptides, with disease-specific immunomodulatory capacity in vivo is limited, however, due to their sensitivity to proteolytic enzymes. Alternative approaches include the development of mimetic molecules which maintain the biological function of an original peptide, yet are stable and able to elicit their response in pharmacological quantities. A novel technique was employed to design a series of semi-mimetic peptides, based on the guinea pig MBP72–85 peptide used to induce EAE in Lewis rats. We used isonipecotic (iNip) and aminocaproic (Acp) acids as templates. Acp-MBP72–85 peptide derived analogues were effective in inducing EAE compared to iNip-peptide analogues which were ineffective at 350μg. These findings suggest that the design and synthesis of semi-mimetic peptide molecules with immunomodulatory potential is possible and that eventually these molecules may form the basis for the development of novel and more effective disease-specific therapeutic agents.
Similar content being viewed by others
References
Marca B, Wauben HM, Boog CJP, Zee R, Joosten I, Scihlief A, Eden W (1992) Disease inhibition by major histocompatibility complex binding peptide analogues of diseaseassociated epitopes: more than blocking alone. J Exp Med 176: 667–677
Chou YK, Vandenbark AA, Jones R, Hashim G, Offner H (1989) Selection of encephalitogenic rat T lymphocyte clones recognizing an immunodominant epitope on myelin basic protein. J Neuros Res 22: 181
Zamvil SS, Steinman L (1990) The T lymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol 8: 579–621
Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, Hafler DA (1994) Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 179: 279–290
Moore GJ, Smith JR, Baylis B, Matsoukas JM (1995) Design and pharmacology of peptide mimetics. Ad Pharmacol 33: 91–141
Matsoukas JM, Hondrelis J, Keramida M, Mavromoustakos T, Makrijannis A, Hamdagni R, Wu Q, Moore GJ (1994) Role of NH2 terminal domain of angiotensin II and [Sar1] angiotensin II on conformation and activity: NMR evidence for aromatic ring clustering and peptide backbone folding compared to [Des1,2,3]-angiotensin II. J Biol Chem 269: 5303–5312
Matsoukas JM, Hondrelis J, Agelis G, Barlos K, Gatos D, Ganter RC, Moore D, Moore GJ (1994) Novel synthesis of cyclic amide-linked analogues of angiotensin II and III. J Med Chem 37: 2958–2669
Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Ann Rev Immunol 10: 153–187
Barlos K, Gatos D, Hondrelis J, Matsoukas J, Moore GJ, Schafer W, Sotiriou P (1989) Preparation of new acid-labile resins of sec-alcohol type and their applications in peptide synthesis. Liebigs Ann Chem 951–955
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tselios, T., Probert, L., Kollias, G. et al. Design and synthesis of small semi-mimetic peptides with immunomodulatory activity based on Myelin Basic Protein (MBP). Amino Acids 14, 333–341 (1998). https://doi.org/10.1007/BF01318852
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01318852